PMID: 11678967Oct 27, 2001

Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels

Diabetic Medicine : a Journal of the British Diabetic Association
I SkrapariN Katsilambros

Abstract

There are scarce data dealing with the degree of postprandial lipaemia after sulphonylurea administration. The aim of this study was to examine the effect of acute glibenclamide administration on postprandial lipaemia in Type 2 diabetic patients. Eight randomly selected Type 2 diabetic individuals, aged 43-65 years (mean, 54 years), who had never received any anti-diabetic drug, were included in the study. Each patient was given a 485 kcal mixed meal (45% fat, 40% carbohydrate and 15% protein) twice on separate days after an overnight fast: once with placebo and once with 5 mg glibenclamide, per os, in a random order. The two tests were performed with an interval of 7 days. Venous blood samples were drawn just before and 2 h, 4 h and 6 h after meal consumption. Total triglyceride levels in plasma, in chylomicrons (CM), in CM-deficient plasma, in very low-density lipoprotein (VLDL) subfractions (VLDL-1, VLDL-2) and in intermediate-density lipoprotein (IDL) were determined. Free fatty acid (FFA) and total cholesterol levels in plasma, as well as high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol levels in CM-deficient plasma, were also measured. Finally, serum glucose, insulin and C-peptide c...Continue Reading

References

Sep 1, 1979·Circulation·D B Zilversmit
Nov 11, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J R PatschW Patsch
May 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·P H GrootL Havekes
May 1, 1989·Scandinavian Journal of Clinical and Laboratory Investigation·M S BillinghamR A Hall
Oct 1, 1988·Diabetic Medicine : a Journal of the British Diabetic Association·S G RainsR S Elkeles
Nov 1, 1988·Diabetes/metabolism Reviews·G M Reaven, Y D Chen
Apr 1, 1987·Diabetes/metabolism Reviews·K PyöräläM Uusitupa
Jun 1, 1995·Current Opinion in Lipidology·M R Taskinen
May 1, 1995·Diabetic Medicine : a Journal of the British Diabetic Association·N Katsilambros
Jan 1, 1993·The Journal of Clinical Endocrinology and Metabolism·Y D ChenG M Reaven
Jan 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·F KarpeAnders Hamsten
Feb 1, 1993·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·C BaynesD G Johnston
Jun 1, 1997·Diabetes/metabolism Reviews·M R Taskinen
Jul 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·R MalmströmM R Taskinen
Jan 15, 1999·Atherosclerosis·N MeroM R Taskinen

Citations

May 8, 2002·Diabetes/metabolism Research and Reviews
Apr 1, 2017·Current Opinion in Cardiology·Niki KatsikiDimitri P Mikhailidis

Related Concepts

Blood Glucose
C-Peptide
Epicholesterol
Chylomicrons
Coronary Heart Disease
Diabetes Mellitus, Non-Insulin-Dependent
Nonesterified Fatty Acids
Neogluconin
Hypoglycemic Effect
Novolin

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.